Bristol Myers Squibb (NYSE:BMY) Stock Rating Raised to Strong-Buy at The Goldman Sachs Group

Posted by Andrew Walz on Oct 17th, 2026

The Goldman Sachs Group upgraded shares of Bristol Myers Squibb (NYSE:BMY – Free Report) from a hold rating to a strong-buy rating in a research note issued to investors on Friday morning,Zacks reports.

A number of other brokerages also recently commented on BMY. Cantor Fitzgerald lowered their target price on Bristol Myers Squibb from $59.00 to $53.00 and set a “neutral” rating on the stock in a research note on Thursday, October 8th. Argus raised Bristol Myers Squibb from a “hold” rating to a “buy” rating and set a $75.00 price target for the company in a research note on Wednesday, August 5th. Royal Bank Of Canada lifted their price target on Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “sector perform” rating in a report on Friday, July 31st. Sanford C. Bernstein reissued a “market perform” rating on shares of Bristol Myers Squibb in a research note on Tuesday. Finally, JPMorgan Chase & Co. raised their price target on shares of Bristol Myers Squibb from $67.00 to $73.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Three analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, fifteen have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $64.88.

Get Our Latest Stock Analysis on BMY

Bristol Myers Squibb Stock Down 1.4%

Shares of Bristol Myers Squibb stock traded down $0.88 on Friday, hitting $59.69. 13,770,205 shares of the company traded hands, compared to its average volume of 14,832,782. The company has a 50-day moving average price of $63.55 and a 200 day moving average price of $60.29. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $68.64. The company has a market cap of $121.94 billion, a PE ratio of 13.15, a PEG ratio of 0.31 and a beta of 0.19.

Bristol Myers Squibb (NYSE:BMY – Get Free Report) last posted its quarterly earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The business had revenue of $12.97 billion for the quarter, compared to the consensus estimate of $11.74 billion. During the same period in the prior year, the business posted $1.46 earnings per share. Bristol Myers Squibb’s revenue for the quarter was up 5.7% compared to the same quarter last year. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. Sell-side analysts predict that Bristol Myers Squibb will post 6.56 earnings per share for the current year.

Bristol Myers Squibb Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, November 2nd. Investors of record on Friday, October 2nd will be paid a $0.63 dividend. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.2%. The ex-dividend date of this dividend is Friday, October 2nd. Bristol Myers Squibb’s dividend payout ratio (DPR) is presently 55.51%.

Insider Buying and Selling at Bristol Myers Squibb

In related news, SVP Phil M. Holzer sold 500 shares of the business’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $67.50, for a total value of $33,750.00. Following the completion of the sale, the senior vice president directly owned 16,862 shares in the company, valued at approximately $1,138,185. The trade was a 2.88% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 0.05% of the company’s stock.

Hedge Funds Weigh In On Bristol Myers Squibb

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BMY. Davis Asset Management L.P. acquired a new stake in shares of Bristol Myers Squibb in the second quarter worth $27,000. Addison Advisors LLC bought a new stake in shares of Bristol Myers Squibb during the 2nd quarter worth $32,000. Bayban bought a new stake in shares of Bristol Myers Squibb during the 4th quarter worth $31,000. Groupe la Francaise grew its stake in Bristol Myers Squibb by 562.9% in the 2nd quarter. Groupe la Francaise now owns 590 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 501 shares during the last quarter. Finally, Kilter Group LLC acquired a new position in Bristol Myers Squibb in the 2nd quarter valued at $35,000. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb News Summary

Here are the key news stories impacting Bristol Myers Squibb this week:

Positive Sentiment: Recent late-stage data support the company’s effort to replace revenue from aging medicines. Bristol Myers Squibb reported positive Phase 3 topline results for RYZ101 in gastroenteropancreatic neuroendocrine tumors and ZENBEXUS (iberdomide) in relapsed or refractory multiple myeloma. The breadth of the pipeline could strengthen long-term growth if the programs successfully reach the market. How Positive Phase 3 Results Will Impact Bristol Myers Squibb Stock Investors
Positive Sentiment: Admilparant remains potentially viable as a pulmonary-fibrosis treatment despite mixed Phase 3 results, with UBS reportedly maintaining a constructive view. The lower dose met the primary endpoint, preserving some commercial potential. Bristol-Myers Squibb’s Pulmonary Fibrosis Treatment Still Viable Despite Recent Mixed Phase 3 Results, UBS Says
Neutral Sentiment: BMY’s roughly 40% one-year rally has been supported by new medicines, revenue growth and higher earnings guidance. However, its low valuation—about 9.36 times forward earnings—suggests investors remain cautious about whether the new portfolio can justify additional upside. Bristol Myers Squibb’s Rally Has Momentum, but Can Its New Drugs Justify More Upside?
Negative Sentiment: The company’s approximately $43 billion debt load and looming patent cliff create concerns about future cash flow and dividend growth. Bristol Myers Squibb’s 4.2% yield and 17-year record of dividend increases may be attractive, but investors are questioning whether upcoming launches can offset declining legacy-drug revenue. Bristol Myers Squibb’s 4.2% Dividend Yield Comes With a Trade-Off Investors Should Know

Bristol Myers Squibb Company Profile

(Get Free Report)

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company that discovers, develops and commercializes prescription medicines. Its research and commercial activities focus primarily on oncology, hematology, immunology, cardiovascular disease and neuroscience. The company serves patients and healthcare providers in the United States and international markets.

Bristol Myers Squibb’s portfolio includes medicines such as Opdivo and Yervoy for certain cancers, Eliquis for the prevention of blood clots and stroke, Revlimid and Pomalyst for blood cancers, and Abraxane for certain solid tumors.